340 related articles for article (PubMed ID: 25218736)
1. Judicious use of biologicals in juvenile idiopathic arthritis.
Zhao Y; Wallace C
Curr Rheumatol Rep; 2014 Nov; 16(11):454. PubMed ID: 25218736
[TBL] [Abstract][Full Text] [Related]
2. Juvenile Idiopathic Arthritis.
Barut K; Adrovic A; Şahin S; Kasapçopur Ö
Balkan Med J; 2017 Apr; 34(2):90-101. PubMed ID: 28418334
[TBL] [Abstract][Full Text] [Related]
3. Treatment of juvenile idiopathic arthritis: a revolution in care.
Stoll ML; Cron RQ
Pediatr Rheumatol Online J; 2014; 12():13. PubMed ID: 24782683
[TBL] [Abstract][Full Text] [Related]
4. The benefit-risk balance for biological agents in juvenile idiopathic arthritis: a meta-analysis of randomized clinical trials.
Cabrera N; Avila-Pedretti G; Belot A; Larbre JP; Mainbourg S; Duquesne A; Janiaud P; Kassai B; Cucherat M; Lega JC
Rheumatology (Oxford); 2020 Sep; 59(9):2226-2236. PubMed ID: 32449926
[TBL] [Abstract][Full Text] [Related]
5. Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry.
Thiele F; Klein A; Windschall D; Hospach A; Foeldvari I; Minden K; Weller-Heinemann F; Horneff G
Rheumatol Int; 2021 Apr; 41(4):751-762. PubMed ID: 33590331
[TBL] [Abstract][Full Text] [Related]
6. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
7. Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis.
Brunner HI; Wong R; Nys M; Kou TD; Dominique A; Martini A; Lovell DJ; Ruperto N;
Paediatr Drugs; 2020 Dec; 22(6):653-672. PubMed ID: 33029724
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab treatment in juvenile idiopathic arthritis patients: A single center experience.
Demir S; Sönmez HE; Arslanoğlu-Aydın E; Özen S; Bilginer Y
Turk J Pediatr; 2019; 61(2):180-185. PubMed ID: 31951328
[TBL] [Abstract][Full Text] [Related]
9. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis.
Tappeiner C; Mesquida M; Adán A; Anton J; Ramanan AV; Carreno E; Mackensen F; Kotaniemi K; de Boer JH; Bou R; de Vicuña CG; Heiligenhaus A
J Rheumatol; 2016 Dec; 43(12):2183-2188. PubMed ID: 27633821
[TBL] [Abstract][Full Text] [Related]
10. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
[TBL] [Abstract][Full Text] [Related]
11. Management of Children with Juvenile Idiopathic Arthritis.
Viswanathan V; Murray KJ
Indian J Pediatr; 2016 Jan; 83(1):63-70. PubMed ID: 26639461
[TBL] [Abstract][Full Text] [Related]
12. Management of Juvenile Idiopathic Arthritis: A Clinical Guide.
Blazina Š; Markelj G; Avramovič MZ; Toplak N; Avčin T
Paediatr Drugs; 2016 Dec; 18(6):397-412. PubMed ID: 27484749
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab for treating juvenile idiopathic arthritis.
Turnier JL; Brunner HI
Expert Opin Biol Ther; 2016; 16(4):559-66. PubMed ID: 26848760
[TBL] [Abstract][Full Text] [Related]
14. Update on biologicals for treatment of juvenile idiopathic arthritis.
Horneff G
Expert Opin Biol Ther; 2013 Mar; 13(3):361-76. PubMed ID: 23289865
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoids in juvenile idiopathic arthritis.
Malattia C; Martini A
Ann N Y Acad Sci; 2014 May; 1318():65-70. PubMed ID: 24738483
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons.
Otten MH; Anink J; Spronk S; van Suijlekom-Smit LW
Ann Rheum Dis; 2013 Nov; 72(11):1806-12. PubMed ID: 23172748
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab for refractory uveitis associated with juvenile idiopathic arthritis: A report of two cases.
Dipasquale V; Atteritano M; Fresta J; Castagna I; Conti G
J Clin Pharm Ther; 2019 Jun; 44(3):482-485. PubMed ID: 30815892
[TBL] [Abstract][Full Text] [Related]
18. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate.
Lovell DJ; Brunner HI; Reiff AO; Jung L; Jarosova K; Němcová D; Mouy R; Sandborg C; Bohnsack JF; Elewaut D; Gabriel C; Higgins G; Kone-Paut I; Jones OY; Vargová V; Chalom E; Wouters C; Lagunes I; Song Y; Martini A; Ruperto N
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665432
[TBL] [Abstract][Full Text] [Related]
20. Comparable Efficacy of Abatacept Used as First-line or Second-line Biological Agent for Severe Juvenile Idiopathic Arthritis-related Uveitis.
Birolo C; Zannin ME; Arsenyeva S; Cimaz R; Miserocchi E; Dubko M; Deslandre CJ; Falcini F; Alessio M; La Torre F; Denisova E; Martini G; Nikishina I; Zulian F
J Rheumatol; 2016 Nov; 43(11):2068-2073. PubMed ID: 27633826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
